CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.

U.S. Dermatology Partners

We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.

Detroit Wayne Mental Health Authority

DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.

Nocimed

Changing the paradigm in spinal diagnosis.